ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Pituitary Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1661983
This article is part of the Research TopicAdvances in Understanding and Managing Skull Base PathologiesView all 3 articles
Malignant Melanoma with Pituitary Metastasis: A Case Report and Literature Review
Provisionally accepted
- 1The Second Hospital of Longyan, Longyan, China
- 2The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: Pituitary metastasis of malignant melanoma (MM) is rare. This study aimed to explore its diagnostic features using a multimodal approach and retrospectively analyzed previously reported cases to summarize its pathogenesis and diagnostic challenges. Methods: We screened all published case reports and case series on pituitary metastatic MM using PubMed, focusing on cases with detailed clinical data, imaging features, pathological examination, and molecular test results. A total of 24 cases of MM with pituitary metastasis, including our case, were retrospectively analyzed. Additionally, the index patient underwent histopathological, immunohistochemical (S100, SOX10, Melan-A, HMB-45, BRAF V600E), and BRAF V600E PCR analyses. Results: This case involved a 65-year-old female patient whose pathological examination revealed tumor cells with epithelioid and spindle cell features. Immunohistochemical analysis showed diffuse positivity for S-100, vimentin, and BRAF V600E, with focal positivity for Melan-A and HMB-45. The Ki-67 proliferation index was approximately 15%. Molecular testing confirmed BRAF V600E mutation. The patient died 12 months postoperatively. Our literature review indicated that MM with pituitary metastasis demonstrates male predominance, a median onset age of 62 years, a frequent association with BRAF V600E mutation, and a median survival time of 12 months. Conclusion: Diagnosing MM with pituitary metastasis requires integrating detailed clinical history, imaging features, pathological examination, and molecular testing. Our findings highlight the importance of a comprehensive diagnostic approach with multidisciplinary collaboration when managing atypical pituitary masses, along with detailed investigation of a patient's previous tumor history, to improve diagnostic accuracy and patient outcomes.
Keywords: Pituitary metastasis, malignant melanoma, Multimodal diagnosis, BRAF V600E, case report
Received: 08 Jul 2025; Accepted: 18 Sep 2025.
Copyright: © 2025 Li, Jiang, Tang, Chen, Deng, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xingfu Wang, wang_xfu@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.